Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

被引:5
作者
Poznyak, Anastasia V. [1 ]
Sukhorukov, Vasily N. [2 ]
Eremin, Ilya I. [3 ]
Nadelyaeva, Irina I. [3 ]
Gutyrchik, Nikita A. [3 ]
Orekhov, Alexander N. [2 ]
机构
[1] Inst Atherosclerosis Res, Osennyaya 4-1-207, Moscow 121609, Russia
[2] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia
[3] Petrovsky Natl Res Ctr Surg, 2 Abrikosovsky Lane, Moscow 119991, Russia
基金
俄罗斯科学基金会;
关键词
PCSK9; atherosclerosis; cardiovascular disease; CVD; lipids; lipid metabolism; LDL RECEPTORS; CARDIOVASCULAR EVENTS; PCSK9; INHIBITION; POOLED ANALYSIS; SAFETY; CHOLESTEROL; EVOLOCUMAB; EFFICACY; DEGRADATION; ALIROCUMAB;
D O I
10.3390/biomedicines11020503
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects. In addition, a regimen with daily administration of the drug is hard to comply with. Thus, there is a need for modern and more efficient therapeutic strategies in CVD treatment. There is extensive evidence indicating that PCSK9 promotes atherogenesis through a variety of mechanisms. Thus, new treatment methods can be developed that prevent or alleviate atherosclerotic cardiovascular disease by targeting PCSK9. Comprehensive understanding of its atherogenic properties is a necessary precondition for the establishment of new therapeutic strategies. In this review, we will summarize the available data on the role of PCSK9 in the development and progression of atherosclerosis. In the last section, we will consider existing PCSK9 inhibitors.
引用
收藏
页数:14
相关论文
共 50 条
[31]   Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction [J].
Schwartz, Gregory G. ;
Giugliano, Robert P. .
CURRENT OPINION IN LIPIDOLOGY, 2022, 33 (03) :147-159
[32]   Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [J].
Reda, Ashraf ;
Elserafy, Ahmed Shawky ;
Farag, Elsayed ;
Mostafa, Tamer ;
Farag, Nabil ;
Elbahry, Atef ;
Sanad, Osama ;
Bendary, Ahmed ;
Elkersh, Ahmed ;
Selim, Mohammed ;
Beshay, Morad ;
Khamis, Hazem .
EGYPTIAN HEART JOURNAL, 2020, 72 (01)
[33]   Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism [J].
Pirro, Matteo ;
Bianconi, Vanessa ;
Francisci, Daniela ;
Schiaroli, Elisabetta ;
Bagaglia, Francesco ;
Sahebkar, Amirhossein ;
Baldelli, Franco .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (12) :3150-3161
[34]   Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community [J].
Kunimura, Ayako ;
Yano, Yuichiro ;
Hisamatsu, Takashi ;
Torii, Sayuki ;
Kondo, Keiko ;
Kadota, Aya ;
Fujiyoshi, Akira ;
Okamura, Tomonori ;
Watanabe, Yoshiyuki ;
Shiino, Akihiko ;
Nozaki, Kazuhiko ;
Ueshima, Hirotsugu ;
Miura, Katsuyuki .
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (05) :1327-1334
[35]   Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9 [J].
Chackerian, Bryce ;
Remaley, Alan .
CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (04) :345-350
[36]   Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience [J].
Galema-Boers, Annette M. H. ;
Lenzen, Mattie J. ;
Sijbrands, Eric J. ;
van Lennep, Jeanine E. Roeters .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (03) :674-681
[37]   Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis [J].
Ferraz-Amaro, I. ;
Delgado-Frias, E. ;
Hernandez-Hernandez, V. ;
Sanchez-Perez, H. ;
de Armas-Rillo, L. ;
Garcia-Dopico, J. A. ;
Diaz-Gonzalez, F. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) :S18-S24
[38]   Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [J].
Julius U. ;
Tselmin S. ;
Schatz U. ;
Fischer S. ;
Bornstein S.R. .
Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) :45-50
[39]   Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults [J].
Gannage-Yared, Marie-Helene ;
Naous, Elie ;
Al Achkar, Anis ;
Issa, Wadih ;
Sleilaty, Ghassan ;
Barakett-Hamade, Vanda ;
Abifadel, Marianne .
METABOLITES, 2022, 12 (08)
[40]   Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial [J].
Rubino, John ;
MacDougall, Diane E. ;
Sterling, Lulu Ren ;
Kelly, Stephanie E. ;
McKenney, James M. ;
Lalwani, Narendra D. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (04) :593-601